PerkinElmer
check quantity

IVISense Pan Cathepsin 680 Fluorescent Probe (ProSense 680)

Proteases perform a fundamental role in protein regulation. Altered activity of lysosomal cathepsins, a class of protease, can indicate many disease-related processes, such as those involved in cancer, inflammation, arthritis, cardiovascular and many others. The ability to detect and quantify normal as well as altered protease cathepsin activity in vivo allows the progress and severity of these disease states to be tracked and interrogated over time.

PerkinElmer’s IVISense Pan Cathepsin fluorescent probes (ProSense®) are versatile pan-cathepsin-activatable NIR agents for imaging various disease-related events. These activatable probes are optically silent in their intact state and become highly fluorescent following protease-mediated cleavage and activation.

For research use only. Not for use in diagnostic procedures.

Part Number
SKU Display Name
List Price
Your Price
Quantity
NEV10003
IVISense Pan Cathepsin 680 Fluorescent Probe (ProSense 680)
717.00 USD
 
more
NEV10001EX
IVISense Pan Cathepsin 750 Fluorescent Probe (ProSense)
767.00 USD
 
more
NEV11171
IVISense Pan Cathepsin 750 FAST Fluorescent Probe (ProSense)
847.00 USD
 
more
Buy Now

Please enter valid quantity

Please log in to add favorites.

NULL OR EMPTY CART

Overview

IVISense Pan Cathepsin 680 is our original “Smart” cathepsin probe; rather than targeting all protease, smart probes become fluorescent only after enzymatic cleavage, which keeps background down and allows detection of activated protease. 24h imaging at 680 nm.

Specifications

Fluorescent Agent Type Activatable
Optical Imaging Classification Fluorescence Imaging
Product Brand Name IVISense
Quantity in a Package Amount 1.0 Units
Shipping Condition Blue Ice
Therapeutic Area Atherosclerosis, Arthritis, Inflammation, Oncology/Cancer
Unit Size 1 Vial (10 doses)
Wave Length 680 nm
Resources, Events & More
  • All

Application Note

In Vivo Imaging of Atherosclerosis Disease Using FMT

Current means of measuring disease in preclinical models of atherosclerosis include ex vivo assessment of disease tissues post-mortem and non-invasive imaging primarily of structural and anatomic features of lesions, in vivo. A non-invasive, quantitative means of imaging known biologic profiles asso ...

PDF 1 MB
Noninvasive In Vivo Quantitation of Asthma Severity Using FMT

Asthma is an inflammatory disease process characterized by reversible airway obstruction and airway hyperresponsiveness. This disease process is driven by activated T lymphocytes and eosinophils that are recruited to the lung upon inhalation of triggering allergens. These cells release inflammatory ...

PDF 488 KB

Ebook

In Vivo Imaging Solutions eBook

Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And ...

PDF 4 MB

Flyer

Best Practices for Designing An Effective In Vivo Fluorescence Imaging Study

Fluorescence molecular imaging is the visualization of cellular and biological function in vivo to gain deeper insights into disease processes and treatment effects. Designing an effective study from the beginning can help save time and resources.

Learn about several important best p ...

PDF 507 KB

Guide

IVISense™ Fluorescent Probe Selector Guide for Oncology Research

The goal of in vivo fluorescence molecular imaging is to enable non-invasive visualization and quantification of cellular and biological functioning to better understand and characterize disease processes and treatment effects earlier within the context of a biological system.

This s ...

PDF 3 MB

Poster

Non-Invasive Near-Infrared Fluorescence Quantitative Tomography (FMT™) of the Effects of PDE4 Inhibitor Therapy in an LPS Murine Model of COPD In Vivo

We demonstrated the ability of the FMT 2500™ in vivo imaging system in combination with two different imaging agents, AngioSense® and ProSense®, to non-invasively visualize and quantify both pulmonary edema and neutrophil protease activity respectively, induced by LPS exposure. The consistency of th ...

PDF 448 KB
Non-Invasive Quantitative Tomography of Disease Progression and Therapeutic Response

We have demonstrated the ability of our Fluorescence Tomography (FMT 2500) in vivo imaging system and ProSense 680 to non-invasively visualize and quantify inflammation in the lung in a robust and validated manner. The consistency of the quantitative tomography, as well as its excellent correlation ...

PDF 581 KB

Technical Note

ProSense 680 (Protocol)

APP_Protocol_ProSense 680 Activatable Fluorescent imaging agent Protocol

PDF 256 KB

White Paper

The Role of In Vivo Imaging in Drug Discovery and Development

The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick ...

PDF 547 KB